Safety-Related Labeling Changes
In animal reproductive studies IRESSA can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment for at least two weeks following completion of therapy.
Trade Name
Iressa
Updated Section
4.6 Fertility, pregnancy and lactation
Month
Mar,2023